Illumina (ILMN)
(Delayed Data from NSDQ)
$117.61 USD
+3.12 (2.73%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $117.69 +0.08 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ILMN 117.61 +3.12(2.73%)
Will ILMN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ILMN
Why Illumina (ILMN) Could Beat Earnings Estimates Again
Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Illumina (ILMN) Upgraded to Buy: Here's Why
Other News for ILMN
Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation
Ensemble Capital Management Q2 2024 Letter
3 Precision Medicine Stocks Tailoring Treatments
Illumina to Present Upcoming Strategy Update
Patient Capital Management Q2 2024 Investment Review